POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change
Rhea-AI Summary
POMDOCTOR (NASDAQ:POM) plans an ADS ratio change, effective on or about June 22, 2026, subject to SEC effectiveness of a post-effective amendment to Form F‑6.
The ratio will change from 1 ADS = 1/6 Class A share to 1 ADS = 3 Class A shares, effectively a 1‑for‑18 reverse ADS split, with no impact on total Class A ordinary shares.
AI-generated analysis. Not financial advice.
Positive
- Reverse ADS split consolidates every 18 existing ADSs into 1 new ADS
- ADS trading price is expected to increase proportionately after the ratio change
- ADSs remain listed on Nasdaq under ticker symbol POM
- No Class A ordinary shares will be issued or cancelled in the ADS Ratio Change
Negative
- ADS holders receive 1 new ADS for every 18 existing ADSs, reducing ADS count
- Fractional ADS entitlements will be sold for cash, less fees, taxes and expenses
- Company gives no assurance ADS price will equal eighteen times prior trading price
News Market Reaction – POM
On the day this news was published, POM declined 8.22%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.5% during that session. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $15.51M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks in the Healthcare/Pharmaceutical Retailers group appeared in the momentum scanner; pre-news action in POM appears stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Full-year earnings | Negative | -3.3% | Revenue growth overshadowed by sharply higher net loss and cash burn. |
| Mar 13 | Strategy update | Positive | +3.3% | Strategic shift toward AI and medical-grade wearables for chronic care. |
| Feb 04 | Platform expansion | Positive | -1.5% | Expanded integration with online medical insurance across Chinese cities. |
| Feb 02 | Nasdaq notice | Negative | +5.2% | Nasdaq deficiency letter for bid price below $1.00 minimum requirement. |
| Jan 16 | Partnerships expansion | Positive | -1.7% | New pharma partnerships to support internet hospital growth and profitability. |
News reactions are mixed, with slightly more divergences than alignments between headline tone and 24-hour price moves.
Over the past months, POMDOCTOR moved from growth initiatives toward addressing listing risk. In January 2026 it highlighted internet hospital partnerships and insurance integration, but shares slipped after both. A February 2 Nasdaq deficiency notice for trading below $1.00 prompted a positive move. Fiscal 2025 results on May 14 showed revenue growth but widening losses and drew a negative reaction. The current ADS ratio change follows this compliance pressure.
Market Pulse Summary
The stock moved -8.2% in the session following this news. A negative reaction despite the ADS consolidation would fit a market focus on underlying fundamentals rather than cosmetic price changes. Before this announcement, POM traded at 0.1156, far below its 1.21 200-day MA and 6.43 52-week high, amid widening losses and going-concern risk disclosed in recent filings. Past news often produced divergent price responses, suggesting sentiment was already fragile.
Key Terms
ads ratio change financial
reverse ads split financial
form f-6 regulatory
direct registration system technical
the depository trust company technical
depositary bank financial
deposit agreement financial
AI-generated analysis. Not financial advice.
For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with the
On the Effective Date, holders of ADSs in the Direct Registration System ("DRS") and in The Depository Trust Company ("DTC") will have their ADSs automatically exchanged and need not take any action. The exchange of every eighteen (18) then-held (existing) ADSs for one (1) new ADS will occur automatically, on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by the depositary bank. Citibank, N.A., as the depositary bank for the Company's ADS program, will arrange for the exchange. The Company's ADSs will continue to be traded on the Nasdaq Stock Market under the ticker symbol "POM."
No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. The ADS Ratio Change will have no impact on the Company's underlying Class A ordinary shares, and no Class A ordinary shares will be issued or cancelled in connection with the ADS Ratio Change.
As a result of the ADS Ratio Change, the trading price of the Company's ADSs is expected to increase proportionately upon the effectiveness of the ADS Ratio Change, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be equal to or greater than eighteen times the ADS trading price before the change.
The depositary bank and the Company have also agreed to amend the deposit agreement, dated as of October 9, 2025, in order to reflect the ADS Ratio Change.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-plan-to-implement-ads-ratio-change-302783087.html
SOURCE POMDOCTOR LIMITED